Genzyme sees another drug shortage; J&J strengthens painkillers' suicide warnings;

 @FiercePharma: J&J vows action as FDA probes side-effect reports. Article | Follow @FiercePharma

> The FDA enforcement action against Genzyme will result in another drug shortage for the company, restricting patient access to a thyroid cancer medicine. Report

> Johnson & Johnson has strengthened warnings about the risk of suicide with its Ultram and Ultracet painkillers after deaths were reported in patients who have histories of emotional disturbance or drug abuse. Report

> Watson Pharmaceuticals invests in $15 million New Jersey expansion. Item

> Celgene said that competitor Barr Laboratories withdrew its application for a generic version of Celgene's cancer drug Thalomid. Release

> More than 50 percent of large drugmakers keep all pharmacovigilance in-house, but among smaller firms--and even some big businesses--outsourcing is considerable, according to a new report. Report

> Irish drugmaker Elan said market instability would not sink a second attempt to spin off its Elan Drug Technologies unit after it failed to sell the drug delivery division in 2008 for that very reason. Report

> Indonesia's biggest pharmaceutical firm PT Kalbe Farma said it plans to spend up to 1 trillion rupiah ($107.4 million) to acquire food and pharmaceutical firms in Southeast Asia. Report

> Generic drugmaker Teva Pharmaceutical Industries Ltd. said Thursday it will spend $56 million to expand a Canadian production plant. Story

Biotech News

 @FierceBiotech: GTx shares dive after toremifene flunks PhIII cancer trial. Article | Follow @FierceBiotech

 @JohnCFierce: So much for Pfizer's two-track approach to R&D, which always looked a tad uncomfortable to me. Now one R&D lord will rule them all.  | Follow @JohnCFierce

> InterMune to chop 60 workers in wake of FDA's rejection. Story

> Noxxon adds to venture backers with €33M round. News

> Logical Therapeutics closes $16.9M round for NSAID program. Article

> Nissen champions a lower-cost trial design for cholesterol med. Story

Vaccines News

> Universal flu vaccine protects mice in Mt. Sinai study. Story

> Study: No benefit to spreading out vaccines. News

> Pfizer Animal Health buys Microtek. Report

> Discredited in U.K., Wakefield champions vax research in U.S. Article

> Immunology research center planned for Kannapolis. News

Manufacturing News

> Genzyme's Termeer has ops insight that Weldon lacks. Item

> J&J has suffered GMP collapse. Story

> Perrigo execs on the hot seat following FDA warning. Article

> Despite concerns, no dietary supplement oversight imminent. News

> AP Pharma CEO walks as board pursues manufacturing fixes. Report

> Genzyme's Lumizyme approved with REMS program. Story

And Finally... The pill is still the No. 1 contraceptive for American women, but it's even more popular in other countries, according to the first government report comparing birth control in various nations. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.